Emergent BioSolutions Inc. Signs $480M Manufacturing Deal
Emergent BioSolutions Inc. has signed a $480M manufacturing deal with Johnson & Johnson to manufacture its COVID-19 vaccine candidate. The new five-year agreement follows a $135M deal dating back to April from Johnson & Johnson that supports large-scale manufacturing of J&J’s lead COVID-19 vaccine candidate at Emergent’s Baltimore City-based manufacturing facility. “We have the expertise and capabilities to meet the long-term needs of our customers and provide ongoing commercial manufacturing to benefit patients,” said Syed Husain, CMDO business unit head at Emergent.